Reuters
10 Aug 2026, 12:06 UTC · 2h ago
Sionna scraps genetic disorder drug program after trial setback; shares tank
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
Reuters
10 Aug 2026, 12:06 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
Sionna Therapeutics is stopping the development of its experimental genetic disorder drug after it failed to show meaningful benefit in a mid-stage trial. — Clinical trial failure for a primary drug candidate typically leads to significant loss of company valuation and investor confidence.
-0.80Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Barrons
3h ago
